Phase 3 Clinical Trials With Primary Completion Dates in July 2019

This is a list of Phase 3 trials with primary completion dates in July 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ALKS Alkermes plc 2019-07-01 Phase 3 NCT03093324 A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
ALNA Allena Pharmaceuticals, Inc. 2019-07-01 Phase 3 NCT03456830 Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria
MNK Mallinckrodt plc 2019-07-01 Phase 3 NCT03005106 StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements
NVCR NovoCure Limited 2019-07-01 Phase 3 NCT02831959 Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
OBSV ObsEva SA 2019-07-01 Phase 3 NCT03070899 Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
RTTR Ritter Pharmaceuticals, Inc. 2019-07-01 Phase 3 NCT03597516 Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
SNY Sanofi 2019-07-01 Phase 3 NCT02993757 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®
ZEAL Zealand Pharma A/S 2019-07-01 Phase 3 NCT03667053 Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children